Acrivon Therapeutics Inc. Common Stock (ACRV)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses whose earnings I can predict and whose competitive position protects them. Acrivon is the opposite kind of speculation: a 74-person clinical-stage oncology company with no revenue in the filed periods and losses in each of the last four years. In fiscal 2025, the year ended 2025-12-31, the net loss was $77.9 million, or $2.02 per diluted share. In fiscal 2024, the net loss was $80.6 million, and in fiscal 2023 it was $60.4 million. The quarterly pattern is similarly heavy: in fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $18.0 million. That is not a business yet; it is a research program financed by shareholders.

In plain English: Acrivon Therapeutics is a small company that is testing cancer treatments and related tests to match patients with drugs. It has no reported sales and has lost money every year for the last four years, so the business looks weak and unproven. At $1.75, the shares look low compared with the value of its net assets on the books, but the losses and cash use are very large compared with the company’s size, so the price is not a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer